ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. Its objective is to provide clinical therapies for the treatment of myelodysplastic syndromes, acute myeloid leukemia, and a range of solid tumor indications. The company was founded by Corey Goodman, Jaume Pons, and K. Christopher Garcia on April 1, 2020 and is headquartered in Burlingame, CA.

$59.06  -0.23 (-0.39%)
As of 06/21/2021 15:59:53 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Mid cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  07/17/2020
Outstanding shares:  40,229,869
Average volume:  185,927
Market cap:   $2,426,263,399
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    00166B105
ISIN:        US00166B1052
Sedol:      BLN7XQ1
Valuation   (See tab for details)
PE ratio:   -170.72
PB ratio:   5.70
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy